In a groundbreaking publication, BrainsWay Ltd. a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has revealed the potential of their Deep Transcranial Magnetic Stimulation (Deep TMS) technology in treating Parkinson’s disease. Clinical data from multiple trials has highlighted significant improvements in both motor and non-motor symptoms among patients. The company has also announced the expansion of Deep TMS availability in South Korea, further solidifying their commitment to providing innovative therapeutic solutions.
Clinical Data Demonstrates Positive Outcomes:Researchers have long explored the potential of noninvasive neurostimulation techniques in alleviating the symptoms of Parkinson’s disease, a debilitating neurodegenerative disorder. BrainsWay’s recent published review showcases the promising results of multiple trials, demonstrating improvements in both motor and non-motor symptoms. This breakthrough could be a game-changer for patients and medical professionals alike, offering new hope and improved quality of life.
Motor Symptoms Improved:Motor symptoms, such as tremors, stiffness, and balance issues, are hallmark characteristics of Parkinson’s disease. The clinical data indicates that Deep TMS has shown significant efficacy in reducing these motor symptoms. By targeting specific brain regions responsible for motor control, Deep TMS stimulates neural circuits and enhances neuronal communication, ultimately leading to improved motor function for patients. This noninvasive approach offers a promising alternative to traditional treatment methods.
Non-Motor Symptoms Addressed:Parkinson’s disease not only affects movement but also impacts various non-motor functions, such as cognition, mood, and sleep patterns. The review highlights that Deep TMS has shown potential in addressing these non-motor symptoms as well. By precisely modulating brain activity, Deep TMS can target and stimulate the areas associated with these functions, offering a comprehensive treatment approach for Parkinson’s disease patients.
Expansion in South Korea:In another significant development, BrainsWay has announced the expansion of Deep TMS availability in South Korea. The company’s continued efforts to expand their noninvasive neurostimulation technology in the country have resulted in recent sales that are expected to increase their installed base to over 20 Deep TMS systems. This expansion highlights BrainsWay’s commitment to making innovative and effective treatments accessible to Parkinson’s disease patients worldwide.
Conclusion:The findings from BrainsWay’s published review provide new hope for individuals living with Parkinson’s disease, showcasing the potential of Deep TMS in improving motor and non-motor symptoms. The expanded availability of Deep TMS in South Korea further solidifies BrainsWay’s position as a global leader in advancing noninvasive neurostimulation treatments. With its groundbreaking technology and commitment to expanding access, BrainsWay is shaping the future of Parkinson’s disease treatment.
Comments